BCL2 and diffuse large B-cell lymphoma: Recent data on a large cohort of DLBCL treated uniformly with rituximab-CHOP also confirmed the negative prognostic relevance of the MYC+/BCL2+ phenotype, with concomitant TP53 mutation conferring an even worse prognosis in such cases [63].